Roche Pharmaceutical Development and Sales Overview

Xolair (omalizumab, RG3648) Humanized monoclonal antibody that selectively binds to IgE Indication Food allergy Phase/study Phase III OUTMATCH1 # of patients N=225 Xolair by SC injection either q2w or q4w for 16 to 20 weeks Design Primary endpoint Number of participants who successfully consume ≥600mg of peanut protein without dose-limiting symptoms Status CT Identifier FPI Q3 2019 In collaboration with Novartis; 1 Sponsor of the study is the National Institute of Allergy and Infectious Diseases (NIAID) IgE-Immunoglobulin E; SC-Subcutaneous NCT03881696 95 Roche Immunology

View entire presentation